12 Best Long Term Low Risk Stocks to Buy Right Now

Page 9 of 12

4. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 106   

Eli Lilly and Company (NYSE:LLY) develops and markets human pharmaceuticals. In Q3 2024, the company reported a 20% increase in worldwide revenue, reaching $11.44 billion, compared to Q3 2023. This growth was driven by a 15% rise in volume and a 6% increase in realized prices. Key contributors included Mounjaro and Zepbound. In December 2024, the firm announced a $3 billion investment to expand its recently acquired facility in Wisconsin. This expansion aims to enhance production capacity for injectable medications like Mounjaro and Zepbound, which collectively generated $4.4 billion in sales in Q3 2024. The company is focusing on advancing its pipeline, particularly in the obesity drug market, which analysts predict could be worth $200 billion by 2031.

Page 9 of 12